Moderna's 5-Year Returns Show Dramatic Timing Impact

Moderna stock has delivered wildly divergent returns depending on purchase timing: a $10,000 investment made in early September 2021 would be worth just $3,792 by early September 2026, while the same amount invested one year ago would now be worth $62,344. The recent surge, exceeding 500% over the past year, follows regulatory approval for updated COVID-19 vaccines and strong clinical trial results for a melanoma treatment developed with Merck, which could potentially lead to vaccines for other cancers and diseases. Despite the stock's volatility, Moderna has posted net losses in recent years, though it holds more cash than debt and possesses proprietary mRNA technology with dozens of pipeline treatments, making it a potentially compelling but risky investment.